Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine, the pharmaceutical company said in a filing with the Taipei Exchange yesterday.
The company yesterday delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say when the regulator would complete its review, the filing showed.
The TGA in November last year gave the Medigen vaccine a provisional determination, the first step to provisional approval, corporate data showed.
Photo: CNA
The step allows for provisional registration of medicines on the basis of preliminary clinical data.
The TGA said it requires comprehensive non-clinical data on safety, quality and compliance with “good manufacturing practice,” the same as for prescription medicine.
The TGA is one of the world’s most credible regulatory authorities as defined by the WHO, Medigen said in the filing.
The COVID-19 vaccines from AstraZeneca PLC, Moderna Inc, Pfizer Inc and BioNTech SE, Johnson & Johnson, and Novavax Inc have obtained provisional approvals from the TGA.
Medigen’s COVID-19 vaccine has been given emergency use authorization in Taiwan and Paraguay, and the company is waiting for a review to be completed in the Kingdom of Eswatini, while New Zealand, Palau, Indonesia, Belize and Thailand exempt travelers who have received the vaccine without requiring strict quarantine measures, it said.
Medigen reported a net loss of NT$140 million (US$4.76 million) in the first quarter, or losses per share of NT$0.66.
First-quarter revenue advanced to NT$326 million from NT$3 million a year earlier, with gross margin of 64 percent.
The company’s operating expenses grew 27.5 percent annually to NT$361 million last quarter due to higher marketing and research spending, company data showed.
SECOND-RATE: Models distilled from US products do not perform the same as the original and undo measures that ensure the systems are neutral, the US’ cable said The US Department of State has ordered a global push to bring attention to what it said are widespread efforts by Chinese companies, including artificial intelligence (AI) start-up DeepSeek (深度求索), to steal intellectual property from US AI labs, according to a diplomatic cable. The cable, dated Friday and sent to diplomatic and consular posts around the world, instructs diplomatic staff to speak to their foreign counterparts about “concerns over adversaries’ extraction and distillation of US AI models.” Distillation is the process of training smaller AI models using output from larger, more expensive ones to lower the costs of training a powerful new
Singapore-based ride-hailing and delivery giant Grab Holdings’ planned acquisition of Foodpanda’s Taiwan operations has yet to enter the formal review stage, as regulators await supplementary documents, the Fair Trade Commission (FTC) said yesterday. Acting FTC Chairman Chen Chih-min (陳志民) told the legislature’s Economics Committee that although Grab submitted its application on March 27, the case has not been officially accepted because required materials remain incomplete. Once the filing is finalized, the FTC would launch a formal probe into the deal, focusing on issues such as cross-shareholding and potential restrictions on market competition, Chen told lawmakers. Grab last month announced that it would acquire
The artificial intelligence (AI) boom has triggered a seismic reshuffling of global equity markets, with Taiwan and South Korea muscling past European nations one by one. With its stock market now valued at nearly US$4.3 trillion, Taiwan surpassed the UK, Europe’s biggest market, earlier this month, data compiled by Bloomberg showed. South Korea is about US$140 billion away from doing the same. The tech-heavy Asian markets have shot past Germany and France in the past seven months. The shift is largely down to massive gains in shares of three companies that provide essential hardware for AI: Taiwan Semiconductor Manufacturing Co (TSMC, 台積電),
Shares of Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) have repeatedly hit new highs, but an equity analyst said the stock’s valuation remains within a reasonable range and any pullback would likely be technical. The contract chipmaker’s historical price-to-earnings (P/E) ratio has ranged between 20 and 30, Cathay Futures Consultant Co (國泰證期) analyst Tsai Ming-han (蔡明翰) told Central News Agency. With market consensus projecting that TSMC would post earnings per share of about NT$100 (US$3.17) this year, supported by strong global demand for artificial intelligence (AI) applications, and the stock currently trading at a P/E ratio of below 25, Tsai said the valuation
RSS